{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"88.1","upperLimit":"100.0","value":"100.0"},{"groupId":"OG001","lowerLimit":"89.8","upperLimit":"99.6","value":"97.1"},{"groupId":"OG002","lowerLimit":"63.1","upperLimit":"100.0","value":"100.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"68"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"description":"Clinical benefit rate was defined as the percentage of participants with best response of minimal response (MR) or better (including sCR, CR, VGPR, PR, and MR). MR was defined as \\>=25% but less than or equal to (\\<=) 49% reduction of serum M-protein and reduction in 24-hour urine M-protein by 50% to 89%. In addition to the above criteria, if present at baseline, \\>=50% reduction in the size of soft tissue plasmacytomas was also required.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received a conditioning regimen of cyclophosphamide 300 milligrams per meter square (mg/m\\^2) intravenous (IV) infusion and fludarabine 30 mg/m\\^2 as IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received target dose of JNJ-68284528 0.75\\*10\\^6 chimeric antigen receptor T (CAR-T) cells per kilogram (cells/kg) (range: 0.5-1.0\\*10\\^6 CAR-positive viable cells/kg) as IV infusion.","id":"OG000","title":"Phase 1b (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received recommended phase 2 dose (RP2D) dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG001","title":"Phase 2 (US Population)"},{"description":"Participants received a conditioning regimen of cyclophosphamide 300 mg/m\\^2 IV infusion and fludarabine 30 mg/m\\^2 IV infusion daily for 3 days from Day -5 to Day -3. On Day 1, participants received RP2D dose of JNJ-68284528 0.75\\*10\\^6 CAR positive viable T cells/kg as IV infusion.","id":"OG002","title":"Phase 2 (Japan Population)"}],"paramType":"NUMBER","populationDescription":"mITT analysis Set included all participants who received a JNJ-68284528 infusion at the targeted RP2D dose level.","reportingStatus":"POSTED","timeFrame":"Pre dose (Day 1) up to 45.2 months","title":"Phase 1b and Phase 2: Clinical Benefit Rate (CBR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}